1. Home
  2. NVCR vs PGNY Comparison

NVCR vs PGNY Comparison

Compare NVCR & PGNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • PGNY
  • Stock Information
  • Founded
  • NVCR 2000
  • PGNY 2008
  • Country
  • NVCR Switzerland
  • PGNY United States
  • Employees
  • NVCR N/A
  • PGNY N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • PGNY Misc Health and Biotechnology Services
  • Sector
  • NVCR Health Care
  • PGNY Health Care
  • Exchange
  • NVCR Nasdaq
  • PGNY Nasdaq
  • Market Cap
  • NVCR 1.9B
  • PGNY 1.8B
  • IPO Year
  • NVCR 2015
  • PGNY 2019
  • Fundamental
  • Price
  • NVCR $17.60
  • PGNY $23.21
  • Analyst Decision
  • NVCR Buy
  • PGNY Buy
  • Analyst Count
  • NVCR 7
  • PGNY 8
  • Target Price
  • NVCR $32.43
  • PGNY $22.86
  • AVG Volume (30 Days)
  • NVCR 1.4M
  • PGNY 1.2M
  • Earning Date
  • NVCR 07-24-2025
  • PGNY 08-07-2025
  • Dividend Yield
  • NVCR N/A
  • PGNY N/A
  • EPS Growth
  • NVCR N/A
  • PGNY N/A
  • EPS
  • NVCR N/A
  • PGNY 0.57
  • Revenue
  • NVCR $621,711,000.00
  • PGNY $1,213,181,000.00
  • Revenue This Year
  • NVCR $5.56
  • PGNY $7.01
  • Revenue Next Year
  • NVCR $9.19
  • PGNY $11.53
  • P/E Ratio
  • NVCR N/A
  • PGNY $40.93
  • Revenue Growth
  • NVCR 18.27
  • PGNY 9.46
  • 52 Week Low
  • NVCR $14.17
  • PGNY $13.39
  • 52 Week High
  • NVCR $34.13
  • PGNY $30.42
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 49.74
  • PGNY 58.94
  • Support Level
  • NVCR $16.81
  • PGNY $21.09
  • Resistance Level
  • NVCR $18.59
  • PGNY $24.66
  • Average True Range (ATR)
  • NVCR 0.74
  • PGNY 0.88
  • MACD
  • NVCR 0.08
  • PGNY 0.26
  • Stochastic Oscillator
  • NVCR 56.18
  • PGNY 66.28

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About PGNY Progyny Inc.

Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.

Share on Social Networks: